"Designing Growth Strategies is in our DNA"
1. Introduction
1.1. ReportOverview
2. Bacterial Pneumonia - Overview
3. Executive Summary
4. Bacterial Pneumonia : Pipeline Assessment
4.1. By Stage ofDevelopment
4.2. By Route ofAdministration
4.3. By DrugClass
4.4. By MoleculeType
4.5. By TherapyArea / Indication
4.6. By DrugTarget
4.7. By Sponsor
5. Bacterial Pneumonia: Company & Drug Profiles
5.1. ClinicalStage
5.1.1. S-649266 – Shionogi Inc.
5.1.1.1. Company Overview
5.1.1.2. Product Description
5.1.1.3. R&D Status & Development Activities
5.1.1.4. Mechanism of Action
5.1.1.5. Molecule Type
5.1.1.6. Stage of Development
5.1.1.7. Indications
5.1.1.8. Route of Administration
5.1.1.9. Funding
5.1.2. Cx611 – TiGenix S.A.U.
5.1.2.1. Company Overview
5.1.2.2. Product Description
5.1.2.3. R&D Status & Development Activities
5.1.2.4. Mechanism of Action
5.1.2.5. Molecule Type
5.1.2.6. Stage of Development
5.1.2.7. Indications
5.1.2.8. Route of Administration
5.1.2.9. Funding
5.1.3. MEDI3902 – MedImmune
5.1.3.1. Company Overview
5.1.3.2. Product Description
5.1.3.3. R&D Status & Development Activities
5.1.3.4. Mechanism of Action
5.1.3.5. Molecule Type
5.1.3.6. Stage of Development
5.1.3.7. Indications
5.1.3.8. Route of Administration
5.1.3.9. Funding
5.1.4. Others
5.2. Preclinical
5.2.1. Company Overview
5.2.2. Product Description
5.2.3. R&D Status & Development Activities
5.2.4. Mechanism of Action
5.2.5. Molecule Type
5.2.6. Indications
5.2.7. Route of Administration
5.2.8. Funding
6. Bacterial Pneumonia: An Overview on Dormant & DiscontinuedPipeline Candidates
6.1. Overview
6.2. ProductDescription
6.3. Reason forDiscontinuation
7. Bacterial Pneumonia: Additional Key Insights
7.1.Epidemiology Overview: Bacterial Pneumonia
7.2. CurrentMarket Scenario: Bacterial Pneumonia Treatment
8. Bacterial Pneumonia: News, Press Releases and Conference Details
Note:
1) This Table of Content is tentative and subject to change as the research progresses.
2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.